此外，艾美疫苗本月初发布公告称，公司自主研发的13价结合肺炎疫苗已向国家药品监督管理局提交药品上市注册。此外，集团控股子公司珠海丽凡达生物技术有限公司研发的mRNA呼吸道合胞病毒(RSV)疫苗已于近日获得国家药品监督管理局出具的《药物临床试验批准通知书》，标志着该疫苗的研发进入了新的阶段。Esprit Pharma (06660) rose more than 7% during the day, up 5.01% as of the writing, trading at 8.18 Hong Kong dollars, with a turnover of 57.4294 million Hong Kong dollars.
According to the Cnstock news app, Esprit Pharma (06660) rose more than 7% during the day, up 5.01% as of the writing, trading at 8.18 Hong Kong dollars, with a turnover of 57.4294 million Hong Kong dollars.
On the news front, Esprit Pharma announced that the group's research and development iterative process efficient human diploid rabies vaccine has recently been submitted to the China Drug Evaluation Center (CDE) of the China National Medical Products Administration for clinical review. It is reported that the group has completed the construction of an iterative process efficient human diploid rabies vaccine workshop that meets international standards, and has completed the production of commercial scale samples for the third phase of clinical trials, demonstrating the ability to produce this product on a large scale.
In addition, Esprit Pharma recently announced at the beginning of this month that the company's independently developed 13-valent combination pneumonia vaccine has been submitted to the National Medical Products Administration for drug registration. Furthermore, the mRNA respiratory syncytial virus (RSV) vaccine developed by the group's holding subsidiary, Zhuhai Livanda Biotechnology Co., Ltd., has recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, marking a new stage in the development of this vaccine.
